HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Galectin Therapeutics +7.75%
Galectin Therapeutics GALT | 3.06 | +7.75% |
HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:
GALT) with a Buy and maintains $11 price target.